ERT of the CXCR4/CXCL12 axis is especially promising in refractory AML patients undergoing alloSCT, as it can destroy malignant cells directly but also dislocate them from their protective niche, rendering them more vulnerable to sequential or combined therapy approaches 26. This evidence concerns the gene CXCR4 and acute myeloid leukemia.